

(Translation)

February 2, 2026

Company name:	Riken Vitamin Co., Ltd.
Name of representative:	Tsutomu Mochizuki President and Representative Director (Securities code: 4526; Tokyo Stock Exchange Prime Market)
Inquiries:	Yoshiya Inoue General Manager of IR & PR Department (Tel: 03-5362-1315)

Notice Regarding the Acquisition Status of Own Shares

Riken Vitamin Co., Ltd. (the "Company") hereby announces the status of the acquisition of its own shares pursuant to Article 156 of the Companies Act, as applied pursuant to Article 165(3) of the Companies Act, as resolved at the meeting of its Board of Directors held on April 30, 2025, as follows.

- | | |
|---|---|
| 1. Class of shares acquired | Common stock |
| 2. Total number of shares acquired | 62,200 shares |
| 3. Total amount of share acquisition cost | 190,219,693 yen |
| 4. Period of acquisition | From January 1, 2026 to January 31, 2026 |
| 5. Method of acquisition | Market purchase on the Tokyo Stock Exchange |

(Reference)

- Details of the resolution at the Board of Directors meeting held on April 30, 2025
 - Class of shares to be acquired Common stock
 - Total number of shares to be acquired 1,000,000 shares (Upper limit)
(3.34% of the total number of shares issued
excluding treasury shares)
 - Total amount of share acquisition cost 2,000,000,000 yen (Upper limit)
 - Period of acquisition From May 26, 2025 to March 24, 2026
 - Method of acquisition Market purchase on the Tokyo Stock Exchange
- Cumulative total of own shares acquired based on the above resolution (as of January 31, 2026)
 - Total number of shares acquired 585,900 shares
 - Total amount of share acquisition cost 1,664,751,327 yen